NCT03256799View on ClinicalTrials.gov

Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations

PHASE4CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 17, 2017

Primary Completion Date

July 10, 2017

Study Completion Date

February 16, 2018

Conditions
Cystic Fibrosis
Interventions
DRUG

Ivacaftor/Ataluren

Both drugs were given in combination for 48 week study period

Trial Locations (1)

35233

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT03256799 - Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations | Biotech Hunter | Biotech Hunter